-
公开(公告)号:US20130150339A1
公开(公告)日:2013-06-13
申请号:US13707096
申请日:2012-12-06
Applicant: Amgen Inc.
Inventor: Christiane BOEZIO , Howard BREGMAN , James R. COATS , Erin F. DIMAURO , Thomas DINEEN , Bingfan DU , Russell GRACEFFA , Charles KREIMAN , Daniel LA , Isaac E. MARX , Nagasree CHAKKA , Hanh Nho NGUYEN , Emily Anne PETERSON , Matthew WEISS , Katrina W. COPELAND , Holly L. DEAK , Alessandro BOEZIO
IPC: C07D498/04 , C07D471/04 , C07D401/14 , C07D417/12 , C07D417/14
CPC classification number: C07D498/04 , C07D239/42 , C07D277/52 , C07D285/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04
Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
Abstract translation: 本发明提供式I化合物或其药学上可接受的盐,其是电压门控钠通道的抑制剂,特别是Nav 1.7。 该化合物可用于治疗可通过抑制钠通道(例如疼痛障碍)治疗的疾病。 还提供含有本发明化合物的药物组合物。
-
公开(公告)号:US20200308145A1
公开(公告)日:2020-10-01
申请号:US16754349
申请日:2018-10-18
Applicant: Amgen Inc.
Inventor: Michael D. BARTBERGER , Nagasree CHAKKA , Hua GAO , Angel GUZMAN-PEREZ , Daniel B. HORNE , Zihao HUA , Madeleine KIEFFER , Daniel C. H. Lin , Benjamin Charles MILGRAM , Jane PANTELEEV , Laurie SCHENKEL , John STELLWAGEN , Matthew WEISS , Ryan D. WHITE , Wei ZHAO
IPC: C07D401/14 , C07D471/10 , C07D471/04 , C07D498/04 , C07D401/04 , C07D403/04 , C07D413/14
Abstract: The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
-